Organon Mircette
Executive Summary
April 22 press release announcing FDA approval of oral contraceptive Mircette implies broader than approved claims. Release implies that because of the treatment regimen's hormone-free days, women "experiencing menstrual migraines and other inter-menstrual side effects such as dysmenorrhea and pre-menstrual syndrome" will be helped. Mircette "is not indicated for these conditions," FDA notes. Press release also implies that Mircette is superior to other OCs because of the hormone free period. "There is no known clinically significant effect of the period of hormone free-days," FDA states